In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model

ABSTRACT In vivo studies have described the pharmacodynamic (PD) characteristics of several triazoles. These investigations have demonstrated that the 24-h area under the concentration-time curve (AUC)/MIC ratio is the critical pharmacokinetic (PK)-PD parameter associated with treatment efficacy. Further analyses from these in vivo studies have demonstrated that a triazole free drug 24-h AUC/MIC of 20 to 25 is predictive of treatment success. We used a neutropenic murine model of disseminated Candida albicans infection to similarly characterize the PK-PD of the new triazole voriconazole. PK and PD parameters (percentage of time that the concentration remains above the MIC [T > MIC], AUC/MIC ratio, and peak level in serum/MIC ratio) were correlated with in vivo efficacy, as measured by the organism number in kidney cultures after 24 h of therapy. Voriconazole kinetics and protein binding were studied in infected neutropenic mice. Peak level/dose and AUC/dose values ranged from 0.1 to 0.2 and 0.1 to 0.7, respectively. The serum elimination half-life ranged from 0.7 to 2.9 h. The level of protein binding in mouse serum was 78%. Treatment efficacy with the four dosing intervals studied was similar, supporting the AUC/MIC ratio as the PK-PD parameter predictive of efficacy. Nonlinear regression analysis also suggested that the AUC/MIC ratio was strongly predictive of treatment outcomes (R2 for AUC/MIC ratio = 82%, R2 for peak level/MIC ratio = 63%, R2 for T > MIC = 75%). Similar studies were conducted with nine additional C. albicans isolates with various voriconazole susceptibilities (MICs, 0.007 to 0.25 μg/ml) to determine if a similar 24-h AUC/MIC ratio was associated with efficacy. The voriconazole free drug AUC/MIC ratios were similar for all of the organisms studied (range, 11 to 58; mean ± standard deviation, 24 ± 17 [P = 0.45]). These AUC/MIC ratios observed for free drug are similar to those observed for other triazoles in this model.

[1]  D. Andes,et al.  In Vivo Pharmacodynamics of a New Triazole, Ravuconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[2]  D. Andes,et al.  In vivo characterization of the pharmacodynamics of the new triazole, posaconazole , in a murine candidiasis model , 2002 .

[3]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[4]  T. C. White,et al.  Resistance Mechanisms in Clinical Isolates of Candida albicans , 2002, Antimicrobial Agents and Chemotherapy.

[5]  M. Pfaller,et al.  In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp , 2002, Antimicrobial Agents and Chemotherapy.

[6]  A. Sugar,et al.  Efficacy of Voriconazole in Treatment of Murine Pulmonary Blastomycosis , 2001, Antimicrobial Agents and Chemotherapy.

[7]  L. See,et al.  Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe CandidaInfections Treated with Fluconazole , 2000, Antimicrobial Agents and Chemotherapy.

[8]  J. Verhoef,et al.  International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). , 1999, Diagnostic microbiology and infectious disease.

[9]  D. Andes,et al.  Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model , 1999, Antimicrobial Agents and Chemotherapy.

[10]  D. Sheehan,et al.  Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.

[11]  D. Reeves.  Clinical Antimicrobial Assays , 1999 .

[12]  S. Dowell,et al.  Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. , 1999, The Pediatric infectious disease journal.

[13]  T. C. White,et al.  Distinct Patterns of Gene Expression Associated with Development of Fluconazole Resistance in Serial Candida albicansIsolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.

[14]  W. Craig,et al.  In Vivo Activities of Amoxicillin and Amoxicillin-Clavulanate against Streptococcus pneumoniae: Application to Breakpoint Determinations , 1998, Antimicrobial Agents and Chemotherapy.

[15]  Michael H. Miller,et al.  Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.

[16]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[17]  M. Ghannoum,et al.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  W. Craig,et al.  Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. , 1996, The Pediatric infectious disease journal.

[19]  Division on Earth.  Guide for the Care and Use of Laboratory Animals , 1996 .

[20]  R. van Furth,et al.  Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice , 1989, Antimicrobial Agents and Chemotherapy.

[21]  J. Turnidge,et al.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.

[22]  J. Galgiani,et al.  Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo , 1986, Antimicrobial Agents and Chemotherapy.

[23]  D. M. Ryan,et al.  Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid , 1982, Antimicrobial Agents and Chemotherapy.

[24]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[25]  W. Craig,et al.  INFLUENCE OF BINDING ON THE PHARMACOLOGIC ACTIVITY OF ANTIBIOTICS , 1973, Annals of the New York Academy of Sciences.

[26]  C. Kunin.  Clinical pharmacology of the new penicillins: I. The importance of serum protein binding in determining antimicrobial activity and concentration in serum , 1966, Clinical pharmacology and therapeutics.